Anti-Obesity Effect of a New Dietary Supplement Consisting of Hydroxycitrate, Carnitine and Red Pepper (3D-Relax Diet) in High-Fat Fed Rats

  • Kim, Kyung-Mi (Neurotide Inc.) ;
  • Ahn, Sang-Wook (Neurotide Inc.,) ;
  • Oh, Sung-Hoon (Department of Food and Biotechnology, Ansan College of Technology) ;
  • Chang, Un-Jae (Department of Food and Nutrition, Dongduk Women's University) ;
  • Kang, Duk-Ho (Department of Social Physical Education, Soonchunhyang University) ;
  • Suh, Hyung-Joo (Department of Food and Nutrition, College of Health Sciences, Korea University)
  • Published : 2003.06.01


Anti-obesity effect of a new dietary supplement (3D-relax) in high-fat fed rats. The aim of this study was to assess the effects of 3D-relax; a proprietary formulation containing hydroxycitrate (233 mg/g), carnitine (150 mg/g) and red pepper (150 mg/g); on body weight, body fat, and serum lipids levels in rats fed a high-fat diet. Male SD 7-wk-old rats (n=8) were fed a high fat diet [52% total dietary energy (E%) from fat, 15.4 E% protein, 32.6E% carbohydrate] with or without 3D-relax administration (1 g/kg body weight/day) for 3 weeks. Administration of 3D-relax significantly reduced the increase in body weight compared to the group fed high fat without 3D-relax. Food efficiency ratio (FER) tended to be decreased with administration of 3D-relax, but was not significant. The perirenal and epididymal fat pad weights of vats administered 3D-relax were significantly lower than those of the high fat group that did not ingest 3D-relax during the 3 weeks. The oral administration of 3D-relax significantly increased HDL-cholesterol level and lowered total cholesterol level compared to those of high fat alone group. These results suggest that 3D-relax reduced body weight and fat gains, and those effects are presumably linked to its inhibitory effects on lipogenesis.


  1. Seidell JC.1995. Obesity in Europe. Obes Res 3: 249-259
  2. Despres JP. 1991. Obesity and lipid metabolism: relevance of body fat distribution. Curr Opin Lipiol 2: 5-15
  3. Bjorntorp P. 1991. Metabolic implications of body fat distribution. Diabetes Care 14: 1132-1143
  4. Kissebah AH. 1991. Insulin resistance in visceral obesity. Int J Obes 15: 109-115
  5. Guy-Grand B. 1997. Pharmacological approaches to intervention. Int J Obes 21: S22-S24
  6. King DJ, Devaney N. 1988. Clinical pharmacology of sibutramine hydrochloride (BTS 54 524), a new antidepressant, in healthy volunteers. Br J Pharmacol 26: 607-611
  7. Kovacs EMR, Westerterp-Plantenga MS, de Vries M. 2001.Effect of 2-week ingestion of (-)-hydroxycitrate and (-)-hydroxycitrate combined with medium-chain triglycerides on satiety and food intake. Physiol Behav 74: 543-549
  8. McCary MF. 1994. Promotion of hepatic lipid oxidation and gluconeogenesis as a strategy for appetite control. Med Hypotheses 42: 215-225
  9. Thom E, Andrew B. 1997. Short- and long-term efficacy and tolerability of (-)-hydoxycitrate in the treatment of obesity. Int J Obes 21: S53-S57
  10. Westerterp-Plantenga MS. 2000. Kovacs EMR: The paradoxal effect of (-)-hydroxycitrate on energy intake regulation in humans. Int J Obes 24: S189-S192
  11. Mattes RD, Bormann L. 2000. Effects of (-)-hydroxycitric acid on appetitive variables. Physiol Behav 71: 87-94
  12. Kawada T, Hagihara KI, Iwai K. 1986. Effects of capsaicin on lipid metabolism in rats fed a high fat diet. J Nutr 116:1272-1278
  13. Choo JJ, Shin HJ. 1999. Body-fat suppressive effects of capsaicin through β-adrenergic stimulation in rats fed a high-fat diet. Korean J Nutr 32: 533-539
  14. Blanchard G, Paragon BM, Millat F, Lutton C. 2002. Dietary L-carnitine supplementation in obese cats alters carnitine metabolism and decreases ketosis during fasting and induced hepatic lipidosis. J Nutr 132: 204-210
  15. Leonhardt M, Hrupka B, Langhans W. 2001. Effect of hydroxycitrate on food intake and body weight regain after a period of restrictive feeding in male rats. Physiol Behav 74: 191-196
  16. McCarty MF, Gustin JC. 1999. Pyruvate and hydroxycitrate/carnitine may synergize to promote reverse electron transport in hepatocyte mitochondria, effectively 'uncoupling the oxidation of fatty acids. Med Hypotheses 52: 407-416
  17. Pola P, Savi L, Grill M. 1980. Carnitine in therapy of dislipidemic patients. Curr Ther Res 27: 208-216
  18. Helms R, Whitington P, Mauer E. 1986. Enhanced lipid utilization in infants receiving oral L-carnitine during long-term parenteral nutrition. J Pediatrics 109: 984-988
  19. Maebashi M, Sato M, Kawamura N. 1978. Lipid-lowering effect of carnitine in patients with type-IV hyperlipoproteinemia. Lancet II: 805-807
  20. Monola P, Belifiore A, Santangelo F, Serricchio M. 1988.L-carnitine on the apolipoprotein pattern of rats fed a cholesterol-rich diet. Comp Biochem Physiol 89B: 69-73
  21. Heo YR, Lee Y, Cha YS. 2002. L-carnitine administration improves lipid metabolism in streptozotocin-induced diabetic rat. Nutr Sci 5: 3-8
  22. Brady LJ, Knoeber CM, Hoppel CL. 1986. Pharmacologic action of L-carnitine on hypertriglyceridemia in obese Zucker rats. Metabolism 35: 555-562